Strategic acquisition to expand availability and fulfill unmet need for opioid and fentanyl overdose solutions.

战略性收购，以扩大阿片类药物和芬太尼过量解决方案的可用性并满足未满足的需求。

SAN DIEGO, June 20, 2024 /PRNewswire/ -- ZMI Pharma, Inc. today announced that it has finalized the acquisition of all strategic assets necessary to manufacture ZIMHI™, including all patents, inventory, automated assembly systems, and the services of two members of the legacy management team.  The business was purchased in its entirety as part of a section 363 sale in the Federal Bankruptcy court.

圣地亚哥，2024年6月20日/PRNewswire/--ZMI Pharma，Inc.今天宣布，它已完成对制造ZIMHI™所需的所有战略资产的收购，包括所有专利、库存、自动组装系统以及遗留管理团队两名成员的服务。作为联邦破产法院第363节出售的一部分，该企业被全部收购。

Further, it announced that it has entered into an agreement with pharmaceutical distributor FFF Enterprises to act as the exclusive distributor of ZIMHI™. ZMI Pharma, Inc. is the manufacturer of record for the product..

此外，该公司宣布已与制药经销商FFF Enterprises签订协议，担任ZIMHI™的独家经销商。ZMI Pharma，Inc.是该产品的记录制造商。。

ZIMHI™ is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, including fentanyl poisoning, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. ZIMHI™ is intended for immediate administration as emergency therapy in settings where opioids may be present.

ZIMHI™是一种阿片类药物拮抗剂，用于紧急治疗已知或疑似阿片类药物过量，包括芬太尼中毒，表现为成人和儿科患者的呼吸和/或中枢神经系统抑郁。ZIMHI™用于在可能存在阿片类药物的环境中作为紧急治疗立即给药。

ZIMHI™ offers the highest dose of naloxone available as an intramuscular injection (5 mg/0.5 mL naloxone hydrochloride solution), and is packaged in a single-dose, pre-filled syringe. It is available by prescription..

ZIMHI™提供最高剂量的纳洛酮肌肉注射（5 mg/0.5 mL盐酸纳洛酮溶液），并包装在单剂量预充注射器中。它可以通过处方获得。。

ZIMHI™ is currently available for purchase from FFF Enterprises for the public interest price of $44.00 per two-dose carton. In order to ensure an uninterrupted supply to customers, ZMI Pharma, Inc. plans to resume the manufacture of ZIMHI™ from its new production facility in Carlsbad, California, in October 2024..

ZIMHI™目前可从FFF企业购买，公共利益价格为每双剂量纸箱44.00美元。为了确保不间断地向客户供应，ZMI Pharma，Inc.计划于2024年10月从其位于加利福尼亚州卡尔斯巴德的新生产设施恢复ZIMHI™的生产。。

John Jellinek, Chief Executive Officer of ZMI Pharma, Inc., commented:

ZMI Pharma，Inc.首席执行官John Jellinek评论道：

'We are excited to be the new manufacturer of ZIMHI™, a medication critical to combating the opioid epidemic in this country. Its high concentration of naloxone and effective delivery system makes ZIMHI™ a crucial tool in the fight against the rising tide of fentanyl poisonings. Our partnership with FFF Enterprises will ensure competitive pricing and timely delivery for our customers, saving countless lives.'.

“我们很高兴成为ZIMHI™的新制造商，ZIMHI™是对抗该国阿片类药物流行的关键药物。其高浓度的纳洛酮和有效的输送系统使ZIMHI™成为对抗芬太尼中毒上升趋势的关键工具。我们与FFF企业的合作关系将确保为我们的客户提供有竞争力的价格和及时的交付，挽救无数人的生命。”。

Patrick M. Schmidt, Chief Executive Officer of FFF Enterprises, Inc., family of companies, commented:

公司家族FFF Enterprises，Inc.首席执行官Patrick M.Schmidt评论道：

'We are pleased to be selected as the exclusive distributor of ZIMHI™. As a result of this agreement, FFF Enterprises is the only pharmaceutical distributor in the U.S. to carry a complete portfolio of naloxone product formulations–including 3 mg, 4 mg, and 8 mg nasal sprays. Our partnership with ZMI Pharma, Inc.

“我们很高兴被选为ZIMHI™的独家经销商。根据该协议，FFF Enterprises是美国唯一一家拥有完整纳洛酮产品配方组合（包括3 mg、4 mg和8 mg鼻喷雾剂）的药品分销商。我们与ZMI Pharma，Inc.的合作伙伴关系。

solidifies our position as a one-stop shop for states and local communities who are looking for targeted, effective ways to save lives.'.

巩固了我们作为州和当地社区一站式商店的地位，他们正在寻找有针对性的有效方法来挽救生命。”。

For further information, visit: https://zimhi.com

欲了解更多信息，请访问：https://zimhi.com

About ZMI Pharma, Inc.

关于ZMI Pharma，Inc。

ZMI Pharma, Inc. is a newly-formed California corporation founded by Richard Hertzberg, John Jellinek, and Sam Kabbani. The founders have significant backgrounds in the life sciences and addiction management businesses, and the management of research and development programs. ZMI Pharma, Inc. will be producing the device in Carlsbad, California, beginning in October 2024.

ZMI Pharma，Inc.是由Richard Hertzberg，John Jellinek和Sam Kabbani成立的新成立的加利福尼亚公司。创始人在生命科学和成瘾管理业务以及研究和开发项目管理方面具有重要背景。ZMI Pharma，Inc.将于2024年10月开始在加利福尼亚州卡尔斯巴德生产该设备。

Current inventories of the device are available from FFF to fulfill existing needs until the new facility is up and running..

FFF可提供设备的当前库存，以满足现有需求，直到新设施建成并运行。。

About FFF Enterprises

关于FFF企业

Since 1988, FFF has been recognized as the nation's leading supplier of critical-care biopharmaceuticals, plasma products (including albumin, intravenous immune globulin and coagulation products) and vaccines. FFF is also known for Helping Healthcare Care®, with a flawless safety track record and an unwavering commitment to customer-driven innovation.

自1988年以来，FFF已被公认为美国重症监护生物制药，血浆产品（包括白蛋白，静脉注射免疫球蛋白和凝血产品）和疫苗的领先供应商。FFF还以帮助Healthcare®而闻名，拥有完美的安全记录，并坚定不移地致力于客户驱动的创新。

Our customers enjoy access to a nationwide salesforce with local representatives, and on-call infusion, specialty pharmacy and reimbursement advisors. With partners that include the largest and most influential GPOs and more than five billion dollars in annual sales, FFF has earned its reputation as the largest and most trusted distributor of human blood products, vaccines and critical-care biopharmaceutical products in the United States..

我们的客户可以通过当地代表、随叫随到的输液、专业药房和报销顾问进入全国范围的销售队伍。FFF拥有包括最大和最具影响力的GPO在内的合作伙伴，年销售额超过50亿美元，已成为美国最大和最值得信赖的人体血液制品、疫苗和重症监护生物制药产品分销商。。

For further information, visit: https://fffenterprises.com/

欲了解更多信息，请访问：https://fffenterprises.com/

SOURCE ZMI Management Inc.

来源ZMI管理公司。